Amerisource Cuts $625M FCA Deal Over Repacked Drugs
By Dorothy Atkins (November 22, 2017, 3:17 PM EST) -- Pharmaceutical giant AmerisourceBergen Corp. has struck a $625 million deal to settle the government's False Claims Act investigation into the drug wholesaler's practice of repackaging and selling injectable drugs, allegedly without regard to product purity, according to documents filed with U.S. securities regulators Tuesday.
The deal was made in principal and is on top of $260 million in fines and forfeitures that Amerisource agreed to pay to resolve a criminal suit. The proposed settlement still needs to be approved by the federal court, according to its 10-K filing with securities regulators, but as it's proposed, the deal is one of the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!